Tag Archives: Abzena

October, 2017

20 October
Abzena and UGA Biopharma Team Up to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis

CAMBRIDGE, England & HENNIGSDORF, Germany–(BUSINESS WIRE)–Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line …
Share

9 October
Roche Acquires Adheron Therapeutics Gaining Rights to a New Autoimmune Disease Drug

CAMBRIDGE, England–(BUSINESS WIRE)–Abzena plc (AIM:ABZA), a life sciences Group providing services and technologies that enable the development and manufacture of biopharmaceutical products, notes the announcement today of the acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Adheron Therapeutics (“Adheron”). Adheron was a privately held biotechnology company developing SDP051, a …
Share